La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MAIA Biotechnology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MAIA Biotechnology..

MAIA Biotechnology (AMEX:MAIA) Azioni, Catena delle Opzioni

MAIA Biotechnology

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

MAIA Biotechnology Inc

Press Releases

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy

Analyst Ratings

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

Penny Stocks

MAIA Biotechnology Announces $2.25 Million Private Placement

MAIA

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Celularity

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

Immix Biopharma

MiNK Therapeutics

INmune Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Medicus Pharma

MediciNova

OS Therapies

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

RenovoRx

Serina Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Noble Capital Markets

Screenshot 2024-09-10 at 8.49.39 PM

Biotech

General

REGN

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Screenshot 2024-06-06 at 5.43.20 PM

New Clinical Data Reveals MAIA Biotechnology&#39;s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

Screenshot 2024-05-21 at 5.35.44 PM

MAIA Biotechnology&#39;s Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market

Comments

MAIA Biotechnology

MAIA Biotechnology (MAIA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO